Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 7:49 PM
Ignite Modification Date:
2025-12-24 @ 7:49 PM
NCT ID:
NCT00412503
Eligibility Criteria:
Inclusion Criteria:
* histologically documented malignant tumor
* refractory or relapsing after conventional treatments and for which there is no curative treatment available
* life expectancy \> 8 weeks
* no significant co-morbidity (NCI-CTC \< 2)
* No organ toxicity
* no chemotherapy within the 4 previous weeks, 6 weeks for nitrosurea or radiotherapy
Exclusion Criteria:
* Hypersensibility to Topotecan and/or Temozolomide or to one of their compounds
* Hypersensibility to Dacarbazine (DTIC)
* Galactosaemia, Glucose and galactose malabsorption syndrom, deficiency in lactase
Sex:
ALL
Minimum Age:
6 Months
Maximum Age:
21 Years
Study:
NCT00412503
Study Brief:
Protocol Section:
NCT00412503